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TO THE EDITOR
Sirtuin 1 (SIRT1), an NAD+-dependent
deacetylase (Imai et al., 2000), acts
as a metabolic sensor that functions on
both histone and non-histone proteins
(Leibiger and Berggren, 2006; Li, 2013).
In this study, we ﬁnd that SIRT1 acti-
vation in animals could inhibit Aldara-
induced psoriasiform lesions. Moreover,
SIRT1–STAT3 interaction may serve as
an important mechanism that underlies
this anti-psoriasis process in keratino-
cytes.
A psoriatic mouse model (The proto-
cols were approved by the Animal Care
and Use Committee at Nanjing Uni-
versity) using Aldara cream (5%
imiquimod, 3 M Pharmaceuticals) on
shaved back skin exhibited signs of
erythema, scaling, and thickening, a
psoriasiform phenotype (van der Fits
et al., 2009; Walter et al., 2013). Histo-
logic examination showed epidermal
hyperplasia and parakeratosis (Figure
1a and b). In addition, the marker
for cellular proliferation Ki-67 and the
marker for abnormal differentiation
of keratinocytes Keratin 17 (Fu and
Wang, 2012) were signiﬁcantly incre-
ased in the lesion epithelia (Figure 1d
and e). The manifestations closely
resembled the characteristics of
psoriatic pathology (Supplementary
Figure S1 online).
Interestingly, the severity of the skin
lesion was signiﬁcantly reduced, when
the mice were treated with an SIRT1
activator resveratrol, before and during
Aldara administration. This resulted
in smoother and thinner skins with
decreased scales and erythemas,
compared with the mice treated with
Aldara only. To determine whether
SIRT1 functioned in this process, a
SIRT1 inhibitor EX527 was applied
to the mice in the same manner.
EX527 treatment exacerbated the
psoriasiform symptoms (Figure 1a). The
score of psoriasis area and the severity
index showed a consistent change
(Figure 1c). Histologically, skin lesions
of resveratrol-treated mice showed
reduced epidermal hyperplasia. In com-
parison, increased epidermal hyper-
plasia and acanthosis were observed
in EX527-treated mice (Figure 1b,
Supplementary Figure S2 online). The
changes in Ki-67 and Keratin 17 levels
in the epithelia were consistent with
the histological alterations (Figure 1d
and e, Supplementary Figure S3A–S3C
online). Furthermore, increased CD4+
immunocyte inﬁltration was observed
in the Aldara-induced lesional skins,
which resembled one of the character-
istics of human psoriatic skin tissues.
The inﬁltration of CD4+ immunocytes
was reduced in the resveratrol group
and increased in the EX527 group
(Figure 1f).
Signal transducer and activator of
transcription 3 (STAT3) is a latent cyto-
plasmic transcription factor that regu-
lates cell growth and differentiation in
response to cytokines (Sano et al.,
2008). Excessive activation of STAT3
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has a key role in psoriasis pathogenesis
(Sano et al., 2005; Andres et al., 2013).
In our study, Aldara treatment also
increased STAT3 phosphorylation in
Tyr705 (PY-STAT3) in the epithelia
of mouse lesion skin. We previously
demonstrated that SIRT1 suppresses
STAT3 phosphorylation by deacetyla-
ting STAT3 key lysine sites in hepatic
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Figure 1. Sirtuin 1 activation counteracted psoriasiform pathology in Aldara-induced mouse skin. (a) Psoriasiform phenotype was induced by Aldara (n= 5).
(b). Parakeratosis (arrows), acanthosis (asterisks), and inﬂammatory inﬁltrates (black arrowheads) were revealed in H&E-stained mouse lesion skin (original
magniﬁcation × 100; n=5). (c) The PASI score indicated disease severity (n=5). (d) Ki-67 immunohistochemical staining in the epithelia (original magniﬁcation
×200; n=5). (e) The relevant proteins of lesion skin were measured by western analysis. The values were normalized to GAPDH. The relative quantitation in
each group (n=5) was expressed as fold induction of its value vs. that of control group. (f) CD4+ cell inﬁltration (red ﬂuorescence, Scale bars: 100 μm) was
detected. (g) PY-STAT3 staining in the epithelia (original magniﬁcation × 200). (h) STAT3 was detected in complexes immunoprecipitated with anti-SIRT1
antibody (n=5). H&E, hematoxylin and eosin staining; PASI, psoriasis area and the severity index; PY-STAT3, STAT3 phosphorylated in Tyr705; STAT3, signal
transducer and activator of transcription 3.
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gluconeogenesis in mice (Nie et al.,
2009). Therefore, we asked whether this
mechanism is involved in the epithelia
in the Aldara-induced psoriasis model.
We found that Aldara treatment decrea-
sed SIRT1 expression and upregulated
acetylated STAT3 (Ac-STAT3), as well
as PY-STAT3, in the lesion skin of mice.
Furthermore, the epithelia of skin lesion
in resveratrol-treated mice showed a
signiﬁcant decrease in Ac-STAT3 and
PY-STAT3, indicating a downregulation
of STAT3 activity in keratinocytes. By
contrast, EX527 treatment upregulated
acetylation and phosphorylation of
STAT3 (Figure 1e and g, Supplemen-
tary Figure S3D online). Both resveratrol
and EX527 act to regulate SIRT1
function by modulating its deacetyla-
tion enzyme activity (Howitz et al., 2003;
Napper et al., 2005). Consistently, no
changes in SIRT1 expression were detec-
ted after resveratrol and EX527 treatment
in this study. To test the association of
STAT3 with SIRT1 in the keratinocytes,
the extracts of mice skin epithelia were
analyzed through co-immunoprecipita-
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Figure 2. Sirtuin 1 counter-regulated signal transducer and activator of transcription 3 (STAT3) activation in human keratinocytes. (a) HaCaTs were stimulated
by IL-6, following a pretreatment with SIRT1 regulators. (b) HaCaTs were incubated for 48 hours after transfection with SIRT1 siRNA or overexpression
plasmid, before IL-6 stimulation. (c) Primary human keratinocytes were treated with SIRT1 regulators before IL-6 stimulation. (d and g) STAT3 was detected
in complexes immunoprecipitated with anti-SIRT1 antibody from the extracts of HaCaTs (d) or human normal skins (n=5; g). (e and f) Cell proliferations
were measured by the MTS assay. *Po0.05. (h) Co-labeled of STAT3 (red) and SIRT1 (green) in parafﬁn sections of human normal skin (n=5). (i) SIRT1
and STAT3 staining (green) in parafﬁn sections of lesion skins from psoriatic patients and normal skins from healthy individuals (n=10). siRNA, small
interfering RNA.
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tion. STAT3 was detected in complexes
immunoprecipitated with anti-SIRT1 anti-
body. However, the binding of STAT3
to SIRT1 was signiﬁcantly reduced in
the Aldara-induced psoriatic lesions
(Figure 1h, Supplementary Figure S3E
online). Overall, these observations
suggest that SIRT1 counteracts the
pathologic effect of Aldara, presumably
through its deacetylation of STAT3 in
keratinocytes.
Next, we studied the role of SIRT1
in human keratinocytes in vitro. First,
the cytokine-induced STAT3 acetylation
and phosphorylation in the HaCaT cells
were signiﬁcantly reduced in response
to pretreatment of SIRT1 activators,
resveratrol, and SRT1720. Conversely,
administration with SIRT1 inhibitor EX527
enhanced STAT3 acetylation and phos-
phorylation (Figure 2a, Supplementary
Figure S4A online). These results were
conﬁrmed by silencing or overexpres-
sing SIRT1 (Figure 2b), which suggests
that SIRT1 negatively regulates STAT3
activation. Moreover, direct interaction
between SIRT1 and STAT3 was detected
(Figure 2d, Supplementary Figure S4B
online).
The effect of SIRT1 on STAT3-depen-
dent keratinocyte proliferation and
differentiation in HaCaT cells were
further determined. As expected, IL-6-
and IL-22-induced cell proliferation
was inhibited by SIRT1 activation, as
well as its ectopic expression (Figure 2e
and f, Supplementary Figure S4C–S4D
online). Keratin 17, a target of STAT3
(Supplementary Figure S4E online) (Shi
et al., 2011), was signiﬁcantly reduced
by SIRT1 activation but enhanced by
SIRT1 inhibition (Figure 2a and b). These
observations were further conﬁrmed in
the primary human keratinocytes (Supple-
mentary Figure S5 online). Resveratrol
treatment downregulated STAT3 acetyla-
tion and phosphorylation and suppressed
the expression of Keratin 17 and cyclin D.
By contrast, EX527 acted in the opposite
direction (Figure 2c).
Moreover, we conﬁrmed SIRT1–
STAT3 interaction in the human skin by
co-immunoprecipitation. The immuno-
ﬂuorescent study revealed the co-
localization between SIRT1 and STAT3
mainly in the basal keratinocytes of epi-
thelium in normal human skin (Figure 2g
and h). A signiﬁcant reduction in SIRT1
in the epithelia was observed in the skin
lesions from psoriatic patients, in compa-
rison with the normal skin from healthy
individuals. Conversely, an increase in
PY-STAT3 was detected in psoriatic skin
lesions (Figure 2i), which is in agreement
with the previous report (Sano et al.,
2005).
These results suggest that SIRT1 dis-
ruption has an important role in Aldara-
induced psoriasiform lesion in mice.
However, whether the development of
pathologic manifestation of psoriasiform
lesion results from SIRT1 disruption in
keratinocytes only or involves other
cells like immunocytes remains uclear.
Moreover, the other functions of resver-
atrol, such as its antioxidation effect,
may not be ruled out in ameliorating the
Aldara-induced psoriasiform phenotype
in mice. Collectively, our study sub-
stantiated SIRT1 as a crucial regulator
for the development of the Aldara-
induced psoriasiform lesion and may
provide a new therapeutic target for
human psoriasis disease.
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